Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1

The requested reference [d7c9860cbe9c547a1e943584b86b48dd1e5473ff] no longer exists in our database. It has been replaced by the current reference: [51c632aeff900d42c712da0b3be5c378408c7bb8]

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The purpose of this study is to evaluate INCB123667 in Combination With BevacizumabVersus Bevacizumab Alone as First‐Line Maintenance Therapy in Participants With AdvancedEpithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Overexpressing CyclinE1.
Epistemonikos ID: 567f607934224bcd66f98f13998c56e5c5f0ddab
First added on: Sep 01, 2026